
David Hillus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9774378/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature Medicine, 2022, 28, 477-480.	30.7	342
2	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1255-1265.	10.7	279
3	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	6.2	125
4	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 2022, 185, 493-512.e25.	28.9	122
5	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerging Infectious Diseases, 2021, 27, 2174-2178.	4.3	67
6	Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. Lancet Respiratory Medicine,the, 2021, 9, e104-e105.	10.7	65
7	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology, 2021, 12, 690698.	4.8	52
8	Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021. Emerging Infectious Diseases, 2021, 27, 2169-2173.	4.3	17
9	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. Clinical Microbiology and Infection, 2021, 27, 1520.e7-1520.e10.	6.0	13
10	Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerging Infectious Diseases, 2022, 28, 1050-1052.	4.3	11